Evidence map›Paper›PMID 28730707›Full record

ArticleJournal of cachexia, sarcopenia and muscle2017

Establishment and characterization of a novel murine model of pancreatic cancer cachexia.

Katherine A Michaelis, Xinxia Zhu, Kevin G Burfeind, Stephanie M Krasnow, Peter R Levasseur, Terry K Morgan, Daniel L Marks

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. ACS nano medicine · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. The effects of tissue inflammation on cancer cachexia.Biochimica et biophysica acta. Molecular basis of disease · 2026
    Review
  13. Interleukin 6 Drives Durable T Cell-Mediated Immunity to Pancreatic Cancer.Cellular and molecular gastroenterology and hepatology · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Katherine A MichaelisMedical Scientist Training Program, Oregon Health and Science University, Portland, USA.ORCID http://orcid.org/0000-0002-3225-3649
Xinxia ZhuPapé Family Pediatric Research Institute, Oregon Health and Science University, Portland, USA.
Kevin G BurfeindMedical Scientist Training Program, Oregon Health and Science University, Portland, USA.
Stephanie M KrasnowPapé Family Pediatric Research Institute, Oregon Health and Science University, Portland, USA.
Peter R LevasseurPapé Family Pediatric Research Institute, Oregon Health and Science University, Portland, USA.
Terry K MorganDepartments of Pathology and Obstetrics and Gynecology, Oregon Health and Science University, Portland, USA.
Daniel L MarksPapé Family Pediatric Research Institute, Oregon Health and Science University, Portland, USA.
Oregon Health & Science University · US

Funding

Testosterone-GnRH Frequency and the Evolution of PCOS in AdolescenceP50HD028934 · NICHD · UNIVERSITY OF VIRGINIA · PI HAISENLEDER, DANIEL J. · 2014 to 2018
$8.6M
(PQD6) Hypothalamic Inflammation in the Initiation of CachexiaR01CA184324 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI MARKS, DANIEL L. · 2014 to 2017
$1.8M
NCI NIH HHS R01 CA184324NICHD NIH HHS P50 HD028934
6 · The paper itself

Abstract

backgroundCachexia is a complex metabolic and behavioural syndrome lacking effective therapies. Pancreatic ductal adenocarcinoma (PDAC) is one of the most important conditions associated with cachexia, with >80% of PDAC patients suffering from the condition. To establish the cardinal features of a murine model of PDAC-associated cachexia, we characterized the effects of implanting a pancreatic tumour cell line from a syngeneic C57BL/6 KRAS

methodsMale and female C57BL/6 mice were inoculated subcutaneously, intraperitoneally, or orthotopically with KPC tumour cells. We performed rigorous phenotypic, metabolic, and behavioural analysis of animals over the course of tumour development.

resultsAll routes of administration produced rapidly growing tumours histologically consistent with moderate to poorly differentiated PDAC. The phenotype of this model was dependent on route of administration, with orthotopic and intraperitoneal implantation inducing more severe cachexia than subcutaneous implantation. KPC tumour growth decreased food intake, decreased adiposity and lean body mass, and decreased locomotor activity. Muscle catabolism was observed in both skeletal and cardiac muscles, but the dominant catabolic pathway differed between these tissues. The wasting syndrome in this model was accompanied by hypothalamic inflammation, progressively decreasing brown and white adipose tissue uncoupling protein 1 (Ucp1) expression, and increased peripheral inflammation. Haematological and endocrine abnormalities included neutrophil-dominant leukocytosis and anaemia, and decreased serum testosterone.

conclusionsSyngeneic KPC allografts are a robust model for studying cachexia, which recapitulate key features of the PDAC disease process and induce a wide array of cachexia manifestations. This model is therefore ideally suited for future studies exploring the physiological systems involved in cachexia and for preclinical studies of novel therapies.

Indexed as

AllograftsAnemiaAnimalsBiopsyBody CompositionCachexiaDisease Models, AnimalEnergy MetabolismFemaleInflammationLeukocytosisLocomotionMagnetic Resonance ImagingMaleMiceMice, TransgenicTestosteroneCachexiaCachexia modelsPancreatic cancerSystemic inflammation

Identifiers

PMID28730707
PMCPMC5659050
OpenAlexW2737050825

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.